← Leaderboard

Infectious

Diarrheal disease

The condition of having at least three loose or liquid bowel movements each day.

Balanced: 5th of 142Biggest burden: 8th of 142Most neglected: 2nd of 142

Living starter kit

Not yet expert-checkedUpdated Nov 13, 2026

Start building on diarrheal disease

Diarrheal disease is a leading cause of death in young children, and large study datasets exist: tens of thousands of children with clinical and stool data, and cohorts that followed children for years. The hard problems are telling which germ actually caused an illness, predicting which children will fall behind in growth afterward, and building triage rules that hold up in new places.

Know diarrheal disease well? No expert has checked this kit yet.Check our work →

Open datasets4

  • GEMS childhood diarrhea study (ClinEpiDB) ↗

    Clinical and stool test data from GEMS, a large case-control study of childhood diarrhea in several countries; downloads need study-team approval.

    22,567 participants in the portal release

    ClinicalApply for accessLicense not stated

  • MAL-ED birth-to-five cohort (ClinEpiDB) ↗

    Data from MAL-ED, which followed children from birth to age five across multiple sites, tracking infections, diet and development; downloads need study-team approval.

    2,145 participants in the portal release

    ClinicalApply for accessLicense not stated

  • Bangladesh and Mali diarrhea cause data ↗

    De-identified data on children with diarrhea in Bangladesh and Mali, with local weather, for predicting whether a virus caused the illness.

    302 children enrolled in the associated validation study

    ClinicalOpen downloadLicense not stated

  • UNICEF diarrhea treatment data ↗

    Country tables from UNICEF on how many children with diarrhea receive recommended treatment.

    EpidemiologyOpen downloadLicense not stated

Benchmarks and tasks3

Open questions4

  1. 01

    Can a model tell viral from other diarrhea in a new place, where different germs are common?

    Knowing an illness is viral lets doctors skip unneeded antibiotics, but the best model differed between Bangladesh and Mali.

    ClinicalEpidemiologySource: External validation of diarrhea etiology prediction ↗

  2. 02

    Can simple measurements identify which children will fall behind in growth after diarrhea, in any setting?

    Falling behind in growth has lifelong effects, and the GEMS-to-MAL-ED study shows how hard it is to carry a rule from one population to another.

    ClinicalSource: Growth-faltering clinical prediction study ↗

  3. 03

    Can dehydration be judged reliably in older children and adults, across clinics?

    Most dehydration guidance was built for young children; NIRUDAK is one of the few studies of older patients.

    ClinicalSource: NIRUDAK derivation study ↗

  4. 04

    Which mix of infections, diet and home environment best predicts later problems in a child's development?

    MAL-ED was designed to study how these factors interact.

    ClinicalEpidemiologySource: MAL-ED programme ↗

Who's working on this4

  • University of Utah and Brown University

    The collaboration tested a phone-based model for predicting viral-only childhood diarrhea in Bangladesh and Mali.

    Its public data and clearly specified predictors make a reproducible modelling task.

    No public invitation foundEvidence, Feb 9, 2022 ↗

  • GEMS team, University of Maryland

    The team coordinated a multi-country case-control study of childhood diarrheal disease.

    Its linked clinical and stool data support work on what causes diarrhea and what follows it.

    No public invitation foundEvidence, date unknown ↗

  • MAL-ED network (FNIH and Fogarty International Center)

    The network studies infection, nutrition and child development across multiple sites.

    Its long-term data supports models of repeated illness and later growth, not just one-off diagnosis.

    No public invitation foundEvidence, date unknown ↗

  • NIRUDAK team, Brown University and icddr,b

    The collaboration built clinical models of dehydration severity in older children and adults with acute diarrhea.

    Published predictors and public workbooks show how a triage model was built.

    No public invitation foundEvidence, Mar 10, 2021 ↗

Not in the kit yet

  • The two biggest datasets, GEMS and MAL-ED, need approval from the study teams to download. None of the datasets states a license, so check terms before commercial use.
  • All three benchmarks are published models to compare against, not live leaderboards.
  • GEMS and MAL-ED shift dates for privacy, which limits fine-grained outbreak modelling.
  • Most data covers young children; the NIRUDAK benchmark is for people older than five.

This kit keeps growing as new data, benchmarks and teams appear. Know something we missed? Tell us →

Get an email when it's expert-checked or gains new datasets, benchmarks or teams.

We'll only email about this kit, and never share your address.

Curated by the Unsolved project team. Every link was checked on the date shown; licenses are as stated by each source.

Where the field stands

  1. 01

    Early understanding

    No strong gene target or drug candidate yet

  2. 02

    Target found

    At least one gene target with strong evidence

  3. 03

    Drug candidates

    Preclinical or phase 1 drug candidates

  4. 04

    In trials

    Drug candidates in phase 2 or later

  5. 05

    Has approved drugs

    At least one approved drug; not necessarily a cure

Derived from Open Targets drug and target data, not self-reported.

Healthy years lost (DALYs), 2023

56.5M

95% range 43.8M to 72.7M

Deaths, 2023

1.1M

People living with it, 2023

61.9M

GBD cause: Diarrheal diseases (exact match)

Research attention

Active clinical trials

150

All clinical trials, ever

1,232

Papers published, 2025

1,111

Active trials per million healthy years lost

2.7

Lower means fewer trials for the size of the problem

What there is to build on

Open Targets Platform ↗

Gene targets with strong evidence

17

of 2,471 associated genes

Top associated genes

MYO5BSLC26A3EPCAMGUCY2CDGAT1

Drugs and clinical candidates

76

Approved drugs

21

Identifiers

Open Targets
MONDO_0001673

Trial and paper counts are rough measures of attention, not of progress. This page is for research planning, not medical advice.